Cepheid Inc (CPHD) 33.40 $CPHD
Cepheid (CPHD): New Tests Drive Growth, Competition Rife
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 7:24AM CDT
With respect to pipeline development, Cepheid's (CPHD) Xpert Trichomonas for male urine claim is currently on track for FDA submission.
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CPHD: 33.40 (+2.03), CRY: 12.23 (+0.25)
Research and Markets - Global Microbiology Testing/Clinical Microbiology Market Value of USD 5.77 Billion by 2021 - Trends, Technologies & Forecasts Report 2016-2021 - Key Vendors: Cepheid, Hologic, Danaher Corp
PR Newswire Europe - Fri Jun 17, 11:11AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
CPHD: 33.40 (+2.03), HOLX: 35.93 (+0.43)
Cepheid Rises 2.96% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 15, 3:43PM CDT
Cepheid (NASDAQ:CPHD) traded in a range yesterday that spanned from a low of $27.90 to a high of $28.98. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $28.85 on volume of 316,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CPHD: 33.40 (+2.03)
Why Investors Love These Scientific & Technical Instruments' Stocks? - Trimble Navigation, Garmin, Cepheid, and Keysight Technologies
PR Newswire - Fri Jun 10, 7:45AM CDT
The Scientific and Technical Instruments industry is a competitive landscape, so while demand for scientific apparatus is high, equities in this space are always scanned by the investor community in regards to their stocks' performance. Ahead of today's trading session, ActiveWallSt.com has issued technical alerts on the following companies: Trimble Navigation Ltd (NASDAQ: TRMB), Garmin Ltd (NASDAQ: GRMN), Cepheid (NASDAQ: CPHD), and Keysight Technologies Inc. (NYSE: KEYS). Learn more about these stocks and access their free alerts by clicking below:
TRMB: 24.04 (+0.17), KEYS: 29.02 (+0.84), CPHD: 33.40 (+2.03), GRMN: 43.37 (+0.78)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.90 (+0.24), SRDX: 24.66 (+0.76), BAX: 46.65 (+0.53), CPHD: 33.40 (+2.03)
Market Has Not Yet Noticed Potential in Cepheid (CPHD); Have You?
Zacks Equity Research - Zacks Investment Research - Fri May 20, 6:53AM CDT
Cepheid is a stock flying under the radar as it looks well positioned for a solid gain given solid estimate revisions and an impressive Zacks Rank
CPHD: 33.40 (+2.03)
Global Biochips Market Worth USD 17.75 Billion by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Abbott Labs, Bio-Rad Labs, Cepheid - Research and Markets
BusinessWire - Mon May 16, 1:09PM CDT
Research and Markets has announced the addition of the "Biochips Market by Type, End user, Fabrication Technology - Forecast to 2020" report to their offering.
ABT: 41.89 (+0.53), CPHD: 33.40 (+2.03)
Europe IVD Market Growth of 4.78% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Abbott, Beckman Coulter, Cepheid - Research and Markets
BusinessWire - Mon May 09, 8:40AM CDT
Research and Markets has announced the addition of the "IVD Market in Europe 2016-2020" report to their offering.
CPHD: 33.40 (+2.03)
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Tue May 03, 7:00AM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
CPHD: 33.40 (+2.03)
US stocks hit by health care woes but avoid bigger losses
By MARLEY JAY - AP - Fri Apr 29, 3:50PM CDT
NEW YORK (AP) — U.S. stocks fell Friday as health care and technology companies continued to report weak first-quarter results, but thanks to some late buying, they managed to avoid major losses.
AMZN: 745.81 (+9.24), TIVO: 10.24 (+0.15), LNKD: 190.44 (+0.24), EXPE: 109.43 (+1.86), CPHD: 33.40 (+2.03), AMGN: 161.10 (+4.51), WDC: 49.35 (+1.69), GRPN: 3.40 (+0.06)
Cepheid (CPHD) Q1 Loss Narrower than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:31AM CDT
Cepheid (CPHD) started 2016 on a compelling note with its first-quarter results exceeding the Zacks Consensus Estimate on both the top and bottom-line front.
BSX: 23.90 (+0.24), BAX: 46.65 (+0.53), CPHD: 33.40 (+2.03), OFIX: 46.70 (+1.09)
Cepheid reports 1Q loss
Automated Insights - Thu Apr 28, 5:11PM CDT
SUNNYVALE, Calif. (AP) _ Cepheid (CPHD) on Thursday reported a first-quarter loss of $6.6 million, after reporting a profit in the same period a year earlier.
CPHD: 33.40 (+2.03)
Cepheid Reports First Quarter 2016 Results
PR Newswire - Thu Apr 28, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today reported revenue for the first quarter of 2016 of $144.8 million, representing growth of 9%, or 13% on a constant currency basis, from $132.6 million for the first quarter of 2015. Net loss was $(6.6) million, or $(0.09) per share, which compares to net income of $0.9 million, or $0.01 per share, in the first quarter of 2015.
CPHD: 33.40 (+2.03)
Cepheid Announces Partner Distribution Agreement With Medline
PR Newswire - Thu Apr 21, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced an agreement with Medline, the largest privately held distributor of healthcare products in the United States, for the distribution of the GeneXpert® System and menu of Xpert® tests spanning healthcare associated infections, critical infectious disease, and sexual health. Under the terms of the non-exclusive agreement, Medline will begin offering the GeneXpert System to non-acute care laboratory customers in the United States, including long-term care facilities with moderately complex labs, physician-office laboratories, women's health and large multi-specialty clinics, urgent care facilities, community health centers, correctional facility laboratories, student health centers, STD clinics, and reference laboratories.
CPHD: 33.40 (+2.03)
Global Molecular Diagnostic Testing for Infectious Diseases Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Cepheid, Illumina, Thermo Fisher - Research and Markets
BusinessWire - Wed Apr 20, 3:57AM CDT
Research and Markets has announced the addition of the "Molecular Diagnostic Testing for Infectious Diseases Global Market Size, Strategies and Forecasts 2016 to 2020 " report to their offering.
CPHD: 33.40 (+2.03)
Using 'Diagnostics First' Could Help Preserve Effectiveness Of Life-Saving Antibiotics
PR Newswire - Mon Apr 11, 2:05AM CDT
Cepheid (Nasdaq: CPHD) today announced the launch of its 'Diagnostics First' campaign to raise awareness for the use of accurate and fast diagnostic tests to inform optimal treatment decisions and avoid over-prescription of the world's limited arsenal of antibiotics.
CPHD: 33.40 (+2.03)
Cepheid Schedules 2016 First Quarter Results Announcement And Webcast
PR Newswire - Thu Apr 07, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2016 first quarter on Thursday, April 28, 2016, after the close of the market.
CPHD: 33.40 (+2.03)
Cepheid Up on International Launch of Next-Gen MRSA Test
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:50PM CDT
Cepheid's (CPHD) Xpert MRSA NxG assay is a next-generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA).
CPHD: 33.40 (+2.03), OFIX: 46.70 (+1.09), HRC: 51.37 (+0.57), OSUR: 6.44 (+0.24)
Cepheid Announces European Approval Of Xpert MRSA Next Generation (NxG) Screening Test
PR Newswire - Tue Mar 29, 7:00AM CDT
Cepheid (Nasdaq: CPHD) today announced commercial availability, outside the United States, of Xpert® MRSA NxG, a next generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA). Xpert MRSA NxG has been updated to identify mecA- and mecC- containing MRSA strains and detect new and emerging SCCmec subtypes with enhanced performance. The assay has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. Xpert MRSA NxG is an important update to the menu of 23 tests available internationally to run on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with over 10,000 systems deployed globally in both developed and emerging market countries.
CPHD: 33.40 (+2.03)
Global Infectious Disease Molecular Diagnostics Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Arca Biopharma, Cepheid, Illumina - Research and Markets
BusinessWire - Fri Mar 25, 7:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hlg9sg/20162020_global) has announced the addition of the "2016-2020 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape" report to their offering.
CPHD: 33.40 (+2.03)
Cepheid (CPHD): New Tests Drive Growth, Competition Rife
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 7:24AM CDT
With respect to pipeline development, Cepheid's (CPHD) Xpert Trichomonas for male urine claim is currently on track for FDA submission.
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CPHD: 33.40 (+2.03), CRY: 12.23 (+0.25)
Research and Markets - Global Microbiology Testing/Clinical Microbiology Market Value of USD 5.77 Billion by 2021 - Trends, Technologies & Forecasts Report 2016-2021 - Key Vendors: Cepheid, Hologic, Danaher Corp
PR Newswire Europe - Fri Jun 17, 11:11AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
CPHD: 33.40 (+2.03), HOLX: 35.93 (+0.43)
Cepheid Rises 2.96% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 15, 3:43PM CDT
Cepheid (NASDAQ:CPHD) traded in a range yesterday that spanned from a low of $27.90 to a high of $28.98. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $28.85 on volume of 316,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CPHD: 33.40 (+2.03)
Why Investors Love These Scientific & Technical Instruments' Stocks? - Trimble Navigation, Garmin, Cepheid, and Keysight Technologies
PR Newswire - Fri Jun 10, 7:45AM CDT
The Scientific and Technical Instruments industry is a competitive landscape, so while demand for scientific apparatus is high, equities in this space are always scanned by the investor community in regards to their stocks' performance. Ahead of today's trading session, ActiveWallSt.com has issued technical alerts on the following companies: Trimble Navigation Ltd (NASDAQ: TRMB), Garmin Ltd (NASDAQ: GRMN), Cepheid (NASDAQ: CPHD), and Keysight Technologies Inc. (NYSE: KEYS). Learn more about these stocks and access their free alerts by clicking below:
TRMB: 24.04 (+0.17), KEYS: 29.02 (+0.84), CPHD: 33.40 (+2.03), GRMN: 43.37 (+0.78)
Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 23.90 (+0.24), SRDX: 24.66 (+0.76), BAX: 46.65 (+0.53), CPHD: 33.40 (+2.03)
Market Has Not Yet Noticed Potential in Cepheid (CPHD); Have You?
Zacks Equity Research - Zacks Investment Research - Fri May 20, 6:53AM CDT
Cepheid is a stock flying under the radar as it looks well positioned for a solid gain given solid estimate revisions and an impressive Zacks Rank
CPHD: 33.40 (+2.03)
Global Biochips Market Worth USD 17.75 Billion by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Abbott Labs, Bio-Rad Labs, Cepheid - Research and Markets
BusinessWire - Mon May 16, 1:09PM CDT
Research and Markets has announced the addition of the "Biochips Market by Type, End user, Fabrication Technology - Forecast to 2020" report to their offering.
ABT: 41.89 (+0.53), CPHD: 33.40 (+2.03)
Europe IVD Market Growth of 4.78% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: Abbott, Beckman Coulter, Cepheid - Research and Markets
BusinessWire - Mon May 09, 8:40AM CDT
Research and Markets has announced the addition of the "IVD Market in Europe 2016-2020" report to their offering.
CPHD: 33.40 (+2.03)
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Tue May 03, 7:00AM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
CPHD: 33.40 (+2.03)
US stocks hit by health care woes but avoid bigger losses
By MARLEY JAY - AP - Fri Apr 29, 3:50PM CDT
NEW YORK (AP) — U.S. stocks fell Friday as health care and technology companies continued to report weak first-quarter results, but thanks to some late buying, they managed to avoid major losses.
AMZN: 745.81 (+9.24), TIVO: 10.24 (+0.15), LNKD: 190.44 (+0.24), EXPE: 109.43 (+1.86), CPHD: 33.40 (+2.03), AMGN: 161.10 (+4.51), WDC: 49.35 (+1.69), GRPN: 3.40 (+0.06)
Cepheid (CPHD) Q1 Loss Narrower than Expected, Sales Top
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:31AM CDT
Cepheid (CPHD) started 2016 on a compelling note with its first-quarter results exceeding the Zacks Consensus Estimate on both the top and bottom-line front.
BSX: 23.90 (+0.24), BAX: 46.65 (+0.53), CPHD: 33.40 (+2.03), OFIX: 46.70 (+1.09)
Cepheid reports 1Q loss
Automated Insights - Thu Apr 28, 5:11PM CDT
SUNNYVALE, Calif. (AP) _ Cepheid (CPHD) on Thursday reported a first-quarter loss of $6.6 million, after reporting a profit in the same period a year earlier.
CPHD: 33.40 (+2.03)
Cepheid Reports First Quarter 2016 Results
PR Newswire - Thu Apr 28, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today reported revenue for the first quarter of 2016 of $144.8 million, representing growth of 9%, or 13% on a constant currency basis, from $132.6 million for the first quarter of 2015. Net loss was $(6.6) million, or $(0.09) per share, which compares to net income of $0.9 million, or $0.01 per share, in the first quarter of 2015.
CPHD: 33.40 (+2.03)
Cepheid Announces Partner Distribution Agreement With Medline
PR Newswire - Thu Apr 21, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced an agreement with Medline, the largest privately held distributor of healthcare products in the United States, for the distribution of the GeneXpert® System and menu of Xpert® tests spanning healthcare associated infections, critical infectious disease, and sexual health. Under the terms of the non-exclusive agreement, Medline will begin offering the GeneXpert System to non-acute care laboratory customers in the United States, including long-term care facilities with moderately complex labs, physician-office laboratories, women's health and large multi-specialty clinics, urgent care facilities, community health centers, correctional facility laboratories, student health centers, STD clinics, and reference laboratories.
CPHD: 33.40 (+2.03)
Global Molecular Diagnostic Testing for Infectious Diseases Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Cepheid, Illumina, Thermo Fisher - Research and Markets
BusinessWire - Wed Apr 20, 3:57AM CDT
Research and Markets has announced the addition of the "Molecular Diagnostic Testing for Infectious Diseases Global Market Size, Strategies and Forecasts 2016 to 2020 " report to their offering.
CPHD: 33.40 (+2.03)
Using 'Diagnostics First' Could Help Preserve Effectiveness Of Life-Saving Antibiotics
PR Newswire - Mon Apr 11, 2:05AM CDT
Cepheid (Nasdaq: CPHD) today announced the launch of its 'Diagnostics First' campaign to raise awareness for the use of accurate and fast diagnostic tests to inform optimal treatment decisions and avoid over-prescription of the world's limited arsenal of antibiotics.
CPHD: 33.40 (+2.03)
Cepheid Schedules 2016 First Quarter Results Announcement And Webcast
PR Newswire - Thu Apr 07, 3:05PM CDT
Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2016 first quarter on Thursday, April 28, 2016, after the close of the market.
CPHD: 33.40 (+2.03)
Cepheid Up on International Launch of Next-Gen MRSA Test
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:50PM CDT
Cepheid's (CPHD) Xpert MRSA NxG assay is a next-generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA).
CPHD: 33.40 (+2.03), OFIX: 46.70 (+1.09), HRC: 51.37 (+0.57), OSUR: 6.44 (+0.24)
Cepheid Announces European Approval Of Xpert MRSA Next Generation (NxG) Screening Test
PR Newswire - Tue Mar 29, 7:00AM CDT
Cepheid (Nasdaq: CPHD) today announced commercial availability, outside the United States, of Xpert® MRSA NxG, a next generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA). Xpert MRSA NxG has been updated to identify mecA- and mecC- containing MRSA strains and detect new and emerging SCCmec subtypes with enhanced performance. The assay has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. Xpert MRSA NxG is an important update to the menu of 23 tests available internationally to run on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with over 10,000 systems deployed globally in both developed and emerging market countries.
CPHD: 33.40 (+2.03)
Global Infectious Disease Molecular Diagnostics Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Arca Biopharma, Cepheid, Illumina - Research and Markets
BusinessWire - Fri Mar 25, 7:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hlg9sg/20162020_global) has announced the addition of the "2016-2020 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape" report to their offering.
CPHD: 33.40 (+2.03)
